Intellia Therapeutics (NTLA) 주식 개요
는 임상 단계 게놈 편집 회사로 CRISPR/Cas9 기반 기술을 사용하여 잠재적으로 치료 가능한 치료제를 개발하는 데 주력하고 있습니다. 자세히 보기
NTLA Community Fair Values
Create NarrativeSee what 111 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ST
stuart_roberts
Community ContributorUS$21.53FV • 64.4% 저평가 내재 할인율
5419.8%Revenue growth p.a.
6.2k
18
0
126
Intellia Therapeutics, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$13.26 |
| 52주 최고가 | US$28.25 |
| 52주 최저가 | US$6.83 |
| 베타 | 1.99 |
| 1개월 변동 | -0.075% |
| 3개월 변동 | 0.84% |
| 1년 변동 | 50.00% |
| 3년 변동 | -69.80% |
| 5년 변동 | -80.43% |
| IPO 이후 변동 | -40.00% |
최근 뉴스 및 업데이트
Intellia Therapeutics And Wall Street Continue To Play Their D&D Game - Data And Doubt
Apr 28
NTLA: Clinical Hold Resolution Will Reopen Key ATTR Phase 3 Catalyst
Narrative Update The analyst price target for Intellia Therapeutics is now set at $25.29. Analysts point to the FDA lifting clinical holds on the MAGNITUDE studies, the resumption of Phase 3 enrollment for nexiguran ziclumeran, and updated trial protocols as key reasons for their revised views.Recent updates
Intellia Therapeutics And Wall Street Continue To Play Their D&D Game - Data And Doubt
Apr 28NTLA: Clinical Hold Resolution Will Reopen Key ATTR Phase 3 Catalyst
Narrative Update The analyst price target for Intellia Therapeutics is now set at $25.29. Analysts point to the FDA lifting clinical holds on the MAGNITUDE studies, the resumption of Phase 3 enrollment for nexiguran ziclumeran, and updated trial protocols as key reasons for their revised views.NTLA: Clinical Hold Resolution Will Restore ATTR Phase 3 Value Driver
Analysts moved Intellia Therapeutics' consolidated price target higher toward the mid to high $20s, citing the FDA's decision to lift clinical holds on the MAGNITUDE programs for nexiguran ziclumeran and noting that the updated safety protocols support the continuation of Phase 3 enrollment. Analyst Commentary Recent Street research highlights a clear shift in sentiment around Intellia Therapeutics following the FDA decision to lift clinical holds on the MAGNITUDE programs and allow Phase 3 enrollment to resume under updated safety protocols.NTLA: Clinical Hold Resolution Will Reopen ATTR Phase 3 Value Opportunity
Analysts lifted their price targets on Intellia Therapeutics toward a range of about $15 to $48 after the FDA removed clinical holds on the MAGNITUDE program, citing improved clarity on safety, updated trial protocols, and a higher assumed probability of success for nexiguran ziclumeran in ATTR indications. Analyst Commentary Research updates following the FDA's decision cluster around how much value investors should assign to nexiguran ziclumeran in transthyretin amyloidosis and how execution risk in Phase 3 might affect Intellia Therapeutics' longer term profile.NTLA: Clinical Hold Resolution Will Restore Confidence In ATTR Phase 3 Franchise
Analysts have raised their blended price target for Intellia Therapeutics from $23.86 to $25.29, citing the FDA's removal of clinical holds on MAGNITUDE studies and renewed confidence in the nex-z program as key reasons for the change. Analyst Commentary Recent research commentary on Intellia Therapeutics clusters around the FDA decision to lift clinical holds on the MAGNITUDE and MAGNITUDE 2 programs for nexiguran ziclumeran, with most firms updating price targets and ratings in response.NTLA: Nex Z Clinical Return Will Ease ATTR Concerns And Support Repricing
Narrative Update on Intellia Therapeutics The analyst price target for Intellia Therapeutics has been raised, with recent moves such as Baird lifting its target to $7 and H.C. Wainwright increasing its target by $10, as analysts point to progress on nex-z returning to the clinic and a broader reassessment of U.S. biopharma valuations. Analyst Commentary Recent Street research on Intellia Therapeutics reflects a mix of optimism tied to specific catalysts and caution around broader sector risks and execution.NTLA: Nex Z Return To Clinic Will Offset ATTR Safety Overhang
Analysts have lifted their fair value estimate for Intellia Therapeutics by about $1.58 per share, supported by recent price target increases from firms citing potential value from a nex-z return to clinic, even as others trim or withdraw targets on safety concerns and a higher assumed future P/E of about 45.5x. Analyst Commentary Recent Street research on Intellia Therapeutics reflects a split view, with some analysts focusing on potential value creation from a nex z return to clinic and others centering on safety concerns and a narrower path to upside.
One Time Genetic Medicines And Late Stage Pipeline Will Redefine Long Term Potential
Catalysts About Intellia Therapeutics Intellia Therapeutics develops CRISPR based genetic medicines aimed at one time treatments for serious diseases. What are the underlying business or industry changes driving this perspective?NTLA: Hereditary Angioedema Progress Will Offset ATTR Liver Safety Concerns
Analysts have trimmed their price targets on Intellia Therapeutics across the board, with several cuts into the single to low double digit US$ range. They are reassessing the risk profile of the ATTR cardiomyopathy program following serious liver toxicity events and related trial pauses and holds.NTLA: Hereditary Angioedema Data Will Drive Future Upside Despite Liver Safety Hold
Intellia Therapeutics' updated analyst price target edges slightly lower as analysts factor in recent safety driven downgrades and target cuts, reflected in a modest reduction in fair value to about $22.27 and a slightly lower forward P/E assumption of roughly 42x. Analyst Commentary Recent Street research on Intellia Therapeutics clusters around the safety questions raised in its ATTR cardiomyopathy program and how those issues flow through to valuation, probability of approval assumptions, and perceived execution risk across the broader platform.NTLA: Hereditary Angioedema Franchise Will Drive Future Upside Despite Ongoing Liver Safety Overhang
Analysts have modestly reduced their average price target on Intellia Therapeutics, trimming fair value by low single digits to around $22 per share, as mounting safety concerns and FDA holds around nexiguran ziclumeran narrow the perceived risk or reward profile despite some lingering optimism on the broader pipeline. Analyst Commentary Street research has turned more cautious on Intellia following the liver safety events in the transthyretin-mediated amyloidosis program, with multiple downgrades and target cuts reflecting a reassessment of risk, probability of approval, and the contribution of nexiguran ziclumeran to long term growth.NTLA: Hereditary Angioedema Program Will Drive Future Upside Despite ATTR Safety Overhang
Analysts have modestly reduced their average price target on Intellia Therapeutics, trimming projected upside by a few dollars per share as mounting liver safety concerns around nexiguran ziclumeran, multiple downgrades, and lowered probability of approval assumptions for the ATTR program weigh more heavily against otherwise intact long term gene editing optionality and the opportunity in hereditary angioedema. Analyst Commentary Street research has turned more cautious on Intellia in the near term, with multiple downgrades and target cuts reflecting heightened uncertainty around the ATTR program and the broader platform safety profile, even as some analysts still highlight long term value in gene editing and the hereditary angioedema franchise.NTLA: Positive Phase 3 Data And Upcoming Regulatory Filing Will Drive Future Upside
Analysts have lowered their average price target on Intellia Therapeutics from approximately $24.85 to $22.43 per share. They cited heightened safety concerns related to recent clinical trial liver toxicity events and uncertainty about the future of key pipeline programs.NTLA: Phase 3 Enrollment Milestones And Data Readouts Will Drive Next Upside
Analysts have reduced their fair value estimate for Intellia Therapeutics from approximately $32.30 to $24.85. They cite heightened safety concerns in key clinical programs and lower projected growth rates following recent adverse events and subsequent trial pauses.Paused Trials Will Drive Rebound After Resolution Of Safety Concerns
Intellia Therapeutics' consensus price target has declined from approximately $34.08 to $32.30 per share. Analysts cite heightened safety concerns surrounding recent liver injury events and paused clinical trials as key drivers behind lower valuation estimates.Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?
Sep 18
Robust In Vivo CRISPR Trials Will Accelerate Therapeutic Success
Despite a notable improvement in both future P/E and net profit margin, Intellia Therapeutics’ consensus analyst price target has been revised downward from $37.11 to $35.23. What's in the News Phase 3 HAELO trial for lonvo-z in hereditary angioedema (HAE) is ongoing, showing strong interim efficacy data; drug has received multiple regulatory designations, including FDA Orphan Drug and RMAT.Analysts Have Made A Financial Statement On Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) First-Quarter Report
May 11Industry Analysts Just Made An Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Revenue Forecasts
May 10
Phase III Trials And Gene Editing Will Bring Promising Therapies
Strategic discontinuation of less promising programs and capital prioritization are expected to improve net margins and enhance commercial prospects.Intellia Trades Lower After Q4 Results As Clinical Progress Fails To Impress
Mar 02Earnings Release: Here's Why Analysts Cut Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Price Target To US$46.08
Mar 02Will Intellia Therapeutics (NASDAQ:NTLA) Spend Its Cash Wisely?
Feb 15Intellia Therapeutics: Buying The Path To Commercialization
Jan 13Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)
Nov 19Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In Focus
Nov 11Data Underwhelms - Intellia's Cash, Data And Competition Are A Challenging Story
Nov 05Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying Opportunity
Oct 25Intellia - Exciting Promise Of First In-Vivo Gene Therapy Makes Bull Case
Sep 25We're Keeping An Eye On Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Rate
Sep 07Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 11Intellia Therapeutics Is Expanding The Scope Of Gene Editing (Technical Analysis)
Aug 03Here's Why It's Unlikely That Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) CEO Will See A Pay Rise This Year
Jun 06Intellia Therapeutics Presents Promising In Vivo CRISPR Results
Jun 05Industry Analysts Just Made A Dazzling Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Revenue Forecasts
May 14Intellia Therapeutics: 3 Near-Term Pivotal In Vivo Gene Therapies
May 13Intellia Therapeutics Is On The Move
Feb 29Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 24Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier
Feb 09Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?
Feb 07Is There An Opportunity With Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) 25% Undervaluation?
Jan 01Intellia Therapeutics (NASDAQ:NTLA) Is In A Good Position To Deliver On Growth Plans
Oct 20주주 수익률
| NTLA | US Biotechs | US 시장 | |
|---|---|---|---|
| 7D | -2.7% | -2.5% | 0.8% |
| 1Y | 50.0% | 26.8% | 27.7% |
수익률 대 산업: NTLA은 지난 1년 동안 30.4%의 수익을 기록한 US Biotechs 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: NTLA은 지난 1년 동안 28.7%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| NTLA volatility | |
|---|---|
| NTLA Average Weekly Movement | 11.2% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
안정적인 주가: NTLA의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.
시간에 따른 변동성: NTLA의 주간 변동성(11%)은 지난 1년 동안 안정적이었지만 US 종목 중 상위 75%보다 높습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2014 | 377 | John Leonard | www.intelliatx.com |
는 임상 단계 게놈 편집 회사로 CRISPR/Cas9 기반 기술을 사용하여 잠재적 치료 치료제를 개발하는 데 주력하고 있습니다. 이 회사는 게놈 편집을 위한 클러스터형, 규칙적으로 간격을 둔 짧은 팔린드로믹 반복("CRISPR")/CRISPR 관련 9("Cas9") 기술을 제공합니다. 이 회사는 질병에 대한 생체 내 및 생체 외 치료법을 발전시키기 위한 모듈식 플랫폼을 제공합니다.
Intellia Therapeutics, Inc. 기초 지표 요약
| NTLA 기초 통계 | |
|---|---|
| 시가총액 | US$1.59b |
| 순이익 (TTM) | -US$412.69m |
| 매출 (TTM) | US$67.67m |
23.1x
주가매출비율(P/S)-3.8x
주가수익비율(P/E)NTLA는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| NTLA 손익계산서 (TTM) | |
|---|---|
| 매출 | US$67.67m |
| 매출원가 | US$324.45m |
| 총이익 | -US$256.78m |
| 기타 비용 | US$155.91m |
| 순이익 | -US$412.69m |
최근 보고된 실적
Dec 31, 2025
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -3.49 |
| 총이익률 | -379.46% |
| 순이익률 | -609.85% |
| 부채/자본 비율 | 0% |
NTLA의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/01 02:11 |
| 종가 | 2026/05/01 00:00 |
| 수익 | 2025/12/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Intellia Therapeutics, Inc.는 36명의 분석가가 다루고 있습니다. 이 중 23명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Jack Allen | Baird |
| Brian Skorney | Baird |
| William Pickering | Bernstein |